Litigation Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
✉ Email this page to a colleague
CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
Docket | ⤷ Try a Trial | Date Filed | 2017-09-06 |
Court | District Court, D. New Jersey | Date Terminated | |
Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
Jury Demand | None | Referred To | Leda D. Wettre |
Patents | 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,855,217; 7,968,569; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 9,056,120; 9,101,621; 9,101,622 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
Biologic Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-12-14 | 90 | 1 The patents-in-suit cover United States Patent Nos. 5,635,517; 6,315,720 (“the ʼ720 patent”); 6,561,977…ʼ720 patent (Count II) 2; the ʼ977 patent (Count III); the ʼ784 patent (Count IV); the ʼ886 patent (Count…prior to the expiration of Celgene’s patents (collectively, “patents-in-suit”). 1 (Id. ¶¶ 1, 39.) …challenging the patent eligibility of Celgene’s Risk Evaluation and Mitigation Strategy patents (“REMS Patents…6,561,977 (“the ʼ977 patent”); 6,755,784 (“the ʼ784 patent”); 7,189,740; 7,465,800; 7,855,217; 7,968,569 | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |